ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2016
Opportunities in immunotherapy of ovarian cancer.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.Journal of ovarian research · 2025Review
- MARVELD1 as a tumor stem cell marker and therapeutic target in visceral obesity-associated ovarian cancer.American journal of cancer research · 2025Article
- Serous Ovarian Carcinoma: Detailed Analysis of Clinico-Pathological Characteristics as Prognostic Factors.Cancers · 2024Article
- Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.Journal of nanobiotechnology · 2024Article
- Characterization of hypoxia-responsive states in ovarian cancer to identify hot tumors and aid adjuvant therapy.Discover oncology · 2024Article
- Research progress of extracellular vesicles in the treatment of ovarian diseases (Review).Experimental and therapeutic medicine · 2024Review
- Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.Journal of cancer research and clinical oncology · 2023Article
- Glucose metabolism and function of CD4Cancer medicine · 2023Article
- PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.Frontiers in immunology · 2023Article
- Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.Cancer immunology, immunotherapy : CII · 2023Article
- Unveiling the novel immune and molecular signatures of ovarian cancer: insights and innovations from single-cell sequencing.Frontiers in immunology · 2023Review
- Review
- CTpathway: a CrossTalk-based pathway enrichment analysis method for cancer research.Genome medicine · 2022Article
- Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.NPJ precision oncology · 2022Article
- Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.Frontiers in immunology · 2022Review
- The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy.American journal of cancer research · 2022Review
- Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy.Frontiers in immunology · 2022Review
- Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines.Oncoimmunology · 2022Article
- Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue.Inflammation · 2021Article
- Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is the most important cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease. Although surgery and chemotherapy can improve survival, the 5-year survival rates remain ominously low at 45%. Novel therapies are urgently needed. The presence of T cells in the OC tumor microenvironment is correlated with improved progression-free and overall survival, while the presence of regulatory T cells and expression of T-cell inhibitory molecules is correlated with a poor prognosis. These data indicate that immunotherapy could hold promise in improving the treatment of OC. In this review, we will discuss the rational of immunotherapy, highlight current results with cancer vaccines, adoptive T-cell therapy and immunomodulatory agents and summarize the immune effects of selected chemotherapeutic and radiotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.